Akebia Therapeutics Announces Participation in Upcoming Investor Conferences
11/24/2021 - 08:30 AM
CAMBRIDGE, Mass. , Nov. 24, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler , Chief Executive Officer, and David A. Spellman , Chief Financial Officer, will participate in the following investor conferences:
Piper Sandler 33rd Annual Virtual Healthcare ConferenceNovember 29 – December 2, 2021 John Butler will participate in a virtual fireside chat, which will be available on the conference site prior to the virtual event.
4th Annual Evercore ISI HealthCONx Conference November 30 - December 2, 2021 John Butler will participate in a virtual fireside chat, which will be presented on Tuesday, November 30 at 4:45 on the conference site.
Where applicable, webcasts of Akebia's fireside chats will be made available on the Investors section of the Company's website at https://ir.akebia.com .
About Akebia Therapeutics Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts . For more information, please visit our website at www.akebia.com , which does not form a part of this release.
Akebia Therapeutics Contact Mercedes Carrasco Mcarrasco@akebia.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-announces-participation-in-upcoming-investor-conferences-301431123.html
SOURCE Akebia Therapeutics
AKBA Rankings
#30 Ranked by Stock Gains
AKBA Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Cambridge
About AKBA
akebia therapeutics, inc. is a biopharmaceutical company headquartered in cambridge, massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (hif) biology. akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. akebia’s global phase 3 program for vadadustat, which includes the pro2tect studies for non-dialysis patients with anemia associated with chronic kidney disease and the inno2vate studies for dialysis-dependent patients, is currently ongoing. for more information, please visit our website at www.akebia.com.